Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3). (Q40480637)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3).	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16632108%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3) (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16632108%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

0 references

attenuated vaccine

1 reference

based on heuristic

inferred from title

Paul Kay-Sheung Chan

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16632108%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Graham Neil Thomas

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16632108%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Violette Sanchez

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16632108%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Sophie Gimenez

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16632108%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Brian Tomlinson

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16632108%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Remi Forrat

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16632108%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Laurent Chambonneau

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16632108%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Florence Deauvieau

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16632108%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Jean Lang

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16632108%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Bruno Guy

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16632108%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

language of work or name

0 references

publication date

4 April 2006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16632108%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16632108%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16632108%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

23

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16632108%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

4914-4926

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16632108%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Dengue: an arthropod-borne disease of global importance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

Comparison by flow cytometry of immune changes induced in human monocyte-derived dendritic cells upon infection with dengue 2 live-attenuated vaccine or 16681 parental strain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

Dengue: defining protective versus pathologic immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

Quantitation of dengue virus specific CD4+ T cells by intracellular cytokine staining

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

Complete nucleotide sequence of dengue type 3 virus genome RNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

T cell responses to an HLA-B*07-restricted epitope on the dengue NS3 protein correlate with disease severity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

Cytokine gene expression and protein production in peripheral blood mononuclear cells of children with acute dengue virus infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

Elevated levels of IL-8 in dengue hemorrhagic fever

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

Early activation of natural killer and B cells in response to primary dengue virus infection in A/J mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

Immunopathogenesis of Dengue hemorrhagic fever

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

Production of interferon alpha by dengue virus-infected human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

A Blunted Blood Plasmacytoid Dendritic Cell Response to an Acute Systemic Viral Infection Is Associated with Increased Disease Severity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

Elevated plasma interleukin-10 levels in acute dengue correlate with disease severity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

Strong HLA class I--restricted T cell responses in dengue hemorrhagic fever: a double-edged sword?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

HLA-A and -B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

An outbreak of primary dengue infection among migrant Chinese workers in Singapore characterized by prominent gastrointestinal symptoms and a high proportion of symptomatic cases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis anti

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

based on heuristic

inferred from DOI database lookup

Serotype-specific T(H)1 responses in recipients of two doses of candidate live-attenuated dengue virus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.066

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40480637&oldid=1494935406"